CDKN2A and neoplasm: In the future, the integration of molecular and genetic markers (e.g., TERT promoter mutations, CDKN2A/B deletions) into risk stratification, along with technological advances and large-scale prospective validation studies, will play a pivotal role in defining the most appropriate and personalized treatment strategies for this challenging tumor subtype.